Page last updated: 2024-09-05

fipamezole and Dyskinesia, Drug-Induced

fipamezole has been researched along with Dyskinesia, Drug-Induced in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brotchie, JM; Fox, SH; Johnston, TH; Piggott, MJ; Savola, JM	1
Coppard, N; Hauser, RA; Leinonen, M; Lewitt, PA; Lu, M; Nicholas, AP; Savola, JM; Weiner, W	1
Brotchie, JM; Crossman, AR; Engstrom, M; Fox, SH; Hill, M; McGuire, SG; Merivuori, H; Savola, JM; Wurster, S	1

Trials

1 trial(s) available for fipamezole and Dyskinesia, Drug-Induced

Article	Year
Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology, 2012, Jul-10, Volume: 79, Issue:2 Topics: Aged; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Imidazoles; Indans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Severity of Illness Index; Treatment Outcome	2012

Other Studies

2 other study(ies) available for fipamezole and Dyskinesia, Drug-Induced

Article	Year
The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates. Movement disorders : official journal of the Movement Disorder Society, 2010, Oct-15, Volume: 25, Issue:13 Topics: Adrenergic alpha-2 Receptor Antagonists; Analysis of Variance; Animals; Disability Evaluation; Disease Models, Animal; Dopamine Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Imidazoles; Indans; Levodopa; Macaca fascicularis; Male; Motor Activity; Parkinsonian Disorders; Time Factors	2010
Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:8 Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Binding, Competitive; Callithrix; Dyskinesia, Drug-Induced; Female; Imidazoles; Indans; Levodopa; Male; Parkinsonian Disorders; Radioligand Assay; Rats; Receptors, Adrenergic; Receptors, AMPA; Receptors, Dopamine; Receptors, GABA; Receptors, Histamine; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin	2003

Article

Year

The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates.

Movement disorders : official journal of the Movement Disorder Society, 2010, Oct-15, Volume: 25, Issue:13

Topics: Adrenergic alpha-2 Receptor Antagonists; Analysis of Variance; Animals; Disability Evaluation; Disease Models, Animal; Dopamine Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Imidazoles; Indans; Levodopa; Macaca fascicularis; Male; Motor Activity; Parkinsonian Disorders; Time Factors

2010

Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:8

Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Binding, Competitive; Callithrix; Dyskinesia, Drug-Induced; Female; Imidazoles; Indans; Levodopa; Male; Parkinsonian Disorders; Radioligand Assay; Rats; Receptors, Adrenergic; Receptors, AMPA; Receptors, Dopamine; Receptors, GABA; Receptors, Histamine; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin

2003